BH 3120
Alternative Names: BH-3120Latest Information Update: 25 Apr 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Apr 2024 Hanmi Pharmaceutical and Merck & Co (MSD) entered into a Clinical Trial Collaboration and Supply Agreement for BH-3120 in Solid tumours
- 23 Apr 2024 Hanmi Pharmaceutical and MSD plans a phase-I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease)
- 28 Dec 2023 Phase-I clinical trials in Solid tumours (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) (NCT06234397)